Optimal Dosing of Prophylactic Enoxaparin after Surgical Procedures: Results of the Double-Blind, Randomized, Controlled FIxed or Variable Enoxaparin (FIVE) Trial

Affiliations

Comment

Eric Swanson. Plast Reconstr Surg. 2022.

. 2022 Apr 1;149(4):831e-832e.

doi: 10.1097/PRS.0000000000008915.

No abstract available

Comment on

Optimal Dosing of Prophylactic Enoxaparin after Surgical Procedures: Results of the Double-Blind, Randomized, Controlled FIxed or Variable Enoxaparin (FIVE) Trial.
Pannucci CJ, Fleming KI, Bertolaccini C, Agarwal J, Rockwell WB, Mendenhall SD, Kwok A, Goodwin I, Gociman B, Momeni A. Pannucci CJ, et al. Plast Reconstr Surg. 2021 Apr 1;147(4):947-958. doi: 10.1097/PRS.0000000000007780. Plast Reconstr Surg. 2021. PMID: 33761517 Clinical Trial.

1. Pannucci CJ, Fleming KI, Bertolaccini C, et al. Optimal dosing of prophylactic enoxaparin after surgical procedures: Results of the double-blind, randomized, controlled fixed or variable enoxaparin (FIVE) trial. Plast Reconstr Surg. 2021;147:947–958.
1. Pannucci CJ, Hunt MM, Fleming KI, Prazak AM. Weight-based dosing for once-daily enoxaparin cannot provide adequate anticoagulation for venous thromboembolism prophylaxis. Plast Reconstr Surg. 2017;140:815–822.
1. Pannucci CJ, Rockwell WB, Ghanem M, Fleming KI, Momeni A, Agarwal J. Inadequate enoxaparin dosing predicts 90-day venous thromboembolism risk among plastic surgery inpatients: An examination of enoxaparin pharmacodynamics. Plast Reconstr Surg. 2017;139:1009–1020.
1. Pannucci CJ, Fleming KI, Agarwal J, Rockwell WB, Prazak AM, Momeni A. The impact of once- versus twice-daily enoxaparin prophylaxis on risk for venous thromboembolism and clinically relevant bleeding. Plast Reconstr Surg. 2018;142:239–249.
1. Sanofi-Aventis U.S. LLC. Lovenox (enoxaparin) information. Available at: https://products.sanofi.us/lovenox/lovenox.pdf . Accessed March 27, 2021.